Working… Menu

Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01375699
Recruitment Status : Completed
First Posted : June 17, 2011
Last Update Posted : August 26, 2019
Information provided by (Responsible Party):
Virginia Commonwealth University

Brief Summary:
Sildenafil increases the therapeutic effect of doxorubicin used as treatment for cancers of solid tumors through both an increase in anti-tumor effects and protection from cardiac toxicity.

Condition or disease Intervention/treatment Phase
Breast Cancer Gastrointestinal Cancer Genitourinary Cancer Sarcoma Gynecologic Cancer Drug: Doxorubicin Drug: Sildenafil Phase 1

Detailed Description:
Definitive study of sildenafil enhancement of anthracycline anticancer effects and cardioprotection would require a randomized, placebo-controlled trial involving large numbers of patients and many years of follow-up. It is appropriate to demonstrate that concurrent administration of sildenafil and doxorubicin is safe and tolerable. Second, in definitive studies it might be helpful to incorporate early markers of cardiac injury in order to gain early insight into cardioprotective effects, but there are no such established markers. As a correlative study, multiple intermediate markers will be tested. In order to investigate these candidate markers it is appropriate to study patients receiving doxorubicin alone, as early markers of injury may not be apparent in patients treated with the combination. In order to accomplish these two goals the trial is a randomized trial involving a sildenafil/doxorubicin group and a doxorubicin group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Open-label Phase 1b Study of Doxorubicin-based Chemotherapy Regimens, With and Without Sildenafil, With Exploratory Analysis of Intermediate Cardiac Markers
Actual Study Start Date : August 11, 2011
Actual Primary Completion Date : August 4, 2017
Actual Study Completion Date : January 19, 2018

Arm Intervention/treatment
Experimental: Sildenafil + doxorubicin

Patients receive sildenafil citrate PO QD* beginning at least 2 days prior to scheduled first dose of doxorubicin hydrochloride and continuing until 2 weeks after last scheduled dose of doxorubicin hydrochloride. Patients also receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.

NOTE: *Patients receive sildenafil citrate PO TID on days that doxorubicin hydrochloride is also administered.

Drug: Doxorubicin
As prescribed by treating provider.
Other Names:
  • 123127
  • Doxorubicin Hydrochloride
  • 3-Hydroxyacetyldaunorubicin Hydrochloride
  • Adriamycin Hydrochloride
  • ADM
  • Adriacin
  • Adriamycin

Drug: Sildenafil
Given PO, by mouth
Other Names:
  • Viagra
  • Revatio
  • Sildenafil Citrate
  • 171599-83-0

Active Comparator: Doxorubicin-based chemotherapy
Patients receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.
Drug: Doxorubicin
As prescribed by treating provider.
Other Names:
  • 123127
  • Doxorubicin Hydrochloride
  • 3-Hydroxyacetyldaunorubicin Hydrochloride
  • Adriamycin Hydrochloride
  • ADM
  • Adriacin
  • Adriamycin

Primary Outcome Measures :
  1. Safety of concurrent sildenafil with doxorubicin-based chemotherapy [ Time Frame: 25 months ]
    Sildenafil will be administered at least 7 days prior to scheduled first dose of doxorubicin and continue daily dosing through 2 weeks after last doxorubicin dose. Multiple biomarkers as candidate early markers of anthracycline-induced cardiotoxicity will be tested.

  2. The difference in left ventricular ejection fraction (LVEF) between arms [ Time Frame: 4 years ]
    A repeated measures analysis of variance (ANOVA) will be used to compare the LVEF between Arm 1 and Arm 2 over all visits. A pooled t-test will also be performed to determine the change in LVEF between first and last visits.

Secondary Outcome Measures :
  1. Comparison of candidate early markers of cardiac injury [ Time Frame: 37 months ]
    The fluctuation in the levels of biomarkers including novel ultra sensitive troponins and BNP, as well as tissue doppler imaging studies with echocardiography will analyzed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with any malignancy that is deemed appropriate for treatment with a chemotherapy regimen incorporating a < 3-hour infusion of doxorubicin >= 40 mg/m^2/dose not more frequently than weekly; single agent doxorubicin and combination chemotherapy are allowed; the duration of treatment and the cumulative dose of doxorubicin are determined by the chemotherapy regimen chosen for treatment of each individual's disease and up to the discretion of the treating provider; prior doxorubicin-based regimen(s) allowed, unless the most recent prior doxorubicin-based regimen resulted in documented refractory disease
  • At least 30 days since last doxorubicin before initiation of current doxorubicin-based regimen
  • Performance status Eastern Cooperative Oncology Group (ECOG) equal to or less than 2
  • Life-expectancy > 1 year
  • Women of childbearing potential and men must agree to use a medically accepted form of birth control for the duration of study and for a minimum of 6 months after the last dose of doxorubicin
  • Ability to understand and the willingness to sign a written informed consent; a signed informed consent must be obtained prior to any study-specific procedures

Exclusion Criteria:

  • Known congestive heart failure (CHF) (active disease or history of)
  • Left ventricular ejection fraction less than 55%
  • Planned concurrent administration of other investigational agents
  • Planned subsequent therapy with a human epidermal growth factor receptor 2 (HER2)-directed treatments (trastuzumab, pertuzumab, trastuzumab emtansine [T-DM1]) or other anthracyclines besides doxorubicin
  • Swallowing or absorption problems that might interfere with oral bioavailability of sildenafil
  • Known hypersensitivity to doxorubicin, sildenafil or any component of either agent
  • Planned chronic nitrate or alpha blocker therapy
  • Exclude persons who require ongoing administration of STRONG cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors and/or inducers; short periods of exposure to CYP3A4 inhibitors will be allowed (i.e., exposure to aprepitant for three days at the time of doxorubicin exposure)
  • Other relative contraindications to sildenafil as defined in the prescribing information:

    • Myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months
    • Coronary artery disease causing unstable angina
    • Resting hypotension (blood pressure [BP] < 90/50) or hypertension (BP > 170/110) despite appropriate treatment
    • Known retinitis pigmentosa
  • Persisting or anticipated toxicity from prior therapy that might confound attribution of on-study adverse events (AEs)
  • Pregnant or nursing
  • Known hearing loss
  • History of priapism when exposed to PDE5 inhibitors (sildenafil, vardenafil, tadalafil)
  • Other condition(s) that in the opinion of the investigator might compromise the objectives of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01375699

Layout table for location information
United States, Virginia
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, United States, 23298-0037
Sponsors and Collaborators
Virginia Commonwealth University
Layout table for investigator information
Principal Investigator: Andrew S. Poklepovic, MD Massey Cancer Center
Publications of Results:
Layout table for additonal information
Responsible Party: Virginia Commonwealth University Identifier: NCT01375699    
Other Study ID Numbers: MCC-13419
NCI-2011-0098 ( Registry Identifier: CTRP )
First Posted: June 17, 2011    Key Record Dates
Last Update Posted: August 26, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Virginia Commonwealth University:
Breast cancer
Gastrointestinal cancer
Genitourinary cancer
Gynecologic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Liposomal doxorubicin
Sildenafil Citrate
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Urological Agents